Sandbox Reserved 1703: Difference between revisions

No edit summary
No edit summary
Line 22: Line 22:


===Intermediate Form===
===Intermediate Form===
No Cryo-EM structures are currently available for the intermediate form, but it is an important state for the full activation of mGlu2. While in the intermediate form, Glutamate, the agonist of mGlu2, binds the agonist binding site. The <scene name='90/904308/Agonist_binding_site/4'>Agonist Binding Site</scene> is formed by both lobes of the VFT. The structure of mGlu2 will still remain in the inactive form upon two glutamates binding. The binding of glutamate, however, promotes signaling down the receptor <ref name="Lin" />.  
No Cryo-EM structures are currently available for the intermediate form, but it is an important state for the full activation of mGlu2. While in the intermediate form, Glutamate, the agonist of mGlu2, binds the agonist binding site. The <scene name='90/904308/Agonist_binding_site/4'>Agonist Binding Site</scene> is formed by both lobes of the VFT. To stabilize the intermediate state, one glutamate will bind, which will cause the closure of one VFT <ref name="Seven" />. mGlu2 will still remain in the inactive after a glutamate is bound. The binding of glutamate promotes signaling down the receptor <ref name="Lin" />.  


===PAM and NAM Bound Form===
===PAM and NAM Bound Form===

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA, Jaime Prilusky, Ashley R. Wilkinson, R. Jeremy Johnson